Webinar Program

STEM CELLS FOR TREATMENT OF COVID19

Webinar hosted by the NSW Stem Cell Network
Sponsored by CCRM Australia and Mesoblast Pty Ltd

SEPTEMBER 10TH 2020 | 12 PM

NSW StemCell NETWORK

NSW STEM CELL NETWORK

The NSW Stem Cell Network is a professional community with an interest in the potential of stem cells to improve the human condition. Stem cell therapies underpin regenerative medicine based technologies.

The Network brings together the scientific, health and medical research communities, the higher education sector and business with the goal of promoting growth and innovation to achieve positive health outcomes for the people of NSW and globally. Our work encompasses science, medicine, ethics, law, business and public awareness of stem cells and regenerative medicine.

Since its establishment in 2002, the Network has pursued its goals, successfully conducting regular workshops, seminars, conferences and courses that allow the knowledge sharing and professional skills development as well as embarking on collaborative research and commercial initiatives. The NSW Stem Cell Network has received infrastructure support from Diabetes NSW.

Stem Cells for the treatment of COVID19

SPEAKERS

SEPTEMBER 10TH 2020 | 12 PM

DR SILVIU ITESCU



"Remestemcel-L for the treatment of acute respiratory distress syndrome, the primary cause of mortality due to COVID-19 infection"

Dr. Silviu Itescu is Chief Executive Officer, Executive Director of Mesoblast Ltd. Prior to founding Mesoblast in 2004, Dr. Itescu established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. He has been a faculty member of Columbia University in New York, and of Melbourne and Monash universities in Australia. In 2011, Dr. Itescu was named BioSpectrum Asia Person of the Year. In 2013, he received the inaugural Key Innovator Award from the Vatican's Pontifical Council for Culture for his leadership in translational science and clinical medicine in relation to adult stem cell therapy. Dr. Itescu has consulted for various international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the board of directors of several publicly listed life sciences companies.

A/PROF REBECCA LIM

"Allogeneic amniotic epithelial cells for lung disease"

Associate Professor Rebecca Lim has been researching the potential and limitations of amniotic epithelial cells in regenerative medicine since 2008. Her research team has uncovered mechanism through which the hAECs modulate inflammatory events and bolster endogenous repair processes. They have demonstrated that hAECs are able to directly influence the stem cell niche in order to bring about tissue regeneration. This work has now progressed to clinical trials across multiple clinical indications including premature babies with bronchopulmonary dysplasia and cerebral palsy, and adults with liver cirrhosis, Crohn's related perianal fistulas and acute ischaemic stroke. Most recently her team has begun to develop an extracellular vesicle biology arm to their research, in an effort to develop a cost-effective approach to regenerative medicine for urgent unmet medical needs.

A/Prof Lim holds joint appointments with the Department of Obstetrics and Gynaecology, Monash University and The Ritchie Centre, Hudson Institute of Medical Research. A/Prof Lim is an NHMRC Career Development Fellow (Industry) where her work aims to bring novel automated solutions to cell manufacturing for the regenerative medicine sector. She was awarded an NHMRC Research Excellence Award in 2019. She is the Scientific Director of the Cell Therapy and Regenerative Medicine Platform at the Monash Health and Translation Precinct, which manufactures cell-based products for early phase clinical trials. She is passionate about clinical translation, patient advocacy and discovery research.

DR KILIAN KELLY

"Cymerus iPSC-derived MSCs in COVID-19 preclinical and clinical perspectives"

Dr Kilian Kelly has approximately 15 years' experience in pharmaceutical/biotechnology research and development, in both commercial and academic settings. Dr Kelly holds a Masters in Pharmacy from Robert Gordon University, Aberdeen and a PhD in Pharmaceutical Sciences from Strathclyde University, Glasgow. He is a registered pharmacist and a member of the Royal Pharmaceutical Society, The Organisation for Professionals in Regulatory Affairs (TOPRA) and the Regulatory Affairs Professionals Society (RAPS).

SPONSORS

SEPTEMBER 10TH 2020 | 12 PM

MESOBLAST

Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogenei cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are:

- **RYONCIL™** (remestemcel-L) for pediatric steroid-refractory acute graft versus host disease
- **Remestemcel-L** for moderate to severe acute respiratory distress syndrome (ARDS), the primary cause of mortality due to COVID-19 infection
- **REVASCOR®** for advanced chronic heart failure, and
- **MPC-06-ID** for chronic low back pain due to degenerative disc disease.

There are currently no United States Food and Drug Administration (FDA)-approved treatments in the United States for children under 12 with steroid-refractory acute graft versus host disease (SR-aGVHD), a potentially life-threatening complication of an allogeneic bone marrow transplant for blood cancer. Mesoblast has filed a Biologics License Application (BLA) with the FDA for approval of its lead allogeneic product candidate RYONCIL for the treatment of SR-aGVHD in children up to 18 years old.

The FDA's Oncologic Drugs Advisory Committee recently voted overwhelmingly (9:1) in favour that the available data support the efficacy of RYONCIL™ in pediatric patients with SR-aGVHD. RYONCIL has been accepted for Priority Review by the FDA with an action date of September 30, 2020, under the Prescription Drug User Fee Act (PDUFA). If approved by the PDUFA date, Mesoblast plans to launch RYONCIL in the United States in Q4 2020.

Mesoblast's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide upon receiving marketing authorizations.

mesoblast

CCRM AUSTRALIA

CCRM Australia is an Australian not-for-profit organisation supporting the development of foundational technologies to accelerate the commercialisation of regenerative medicine products and therapies. CCRM Australia's focus is to bridge the commercialisation gap through a network of scientists, entrepreneurs, academic institutions and industry partners and address bottlenecks in the industry.

CCRM Australia is modelled on the highly successful CCRM in Canada and is legally separate to CCRM. As a member of the Global CCRM network, CCRM Australia is a partner to a leading-edge industry consortium. CCRM Australia is supported by MTPConnect and the Victorian State Government.